Introduction
Tumor suppressor p53 is essential for normal cell growth, development and dierentiation. A way to regulate p53 function is interaction with Mdm2, since Mdm2 can regulate stability of p53 via degradation (Haupt et al., 1997; Kubbutat et al., 1997) . Thus, it can inhibit p53 dependent cell-cycle arrest or apoptosis (Haupt et al., 1993; Chen et al., 1996) . In addition to direct Mdm2-p53 protein interactions via complexing, p53 controls transcriptional activity of mdm2, resulting in an autoregulative feedback loop Wu et al., 1993) . Disturbances of the ®ne regulated balance between p53 and Mdm2 can result in uncontrolled cell growth and subsequent tumorigenesis.
Alterations of p53 and Mdm2 are usually described as alternative events in soft tissue sarcoma (STS) tumorigenesis (Leach et al., 1993; Florenes et al., 1994) . In contrast to the prognostic relevance of p53 changes in STS (Cordon-Cardo et al., 1994; Taubert et al., 1996; WuÈ rl et al., 1997) , the clinical value of Mdm2 alterations has not been investigated suciently in STS up to now. This background prompted us to evaluate the possible prognostic relevance of simultaneous Mdm2 and p53 overexpression in STS by multivariate analysis.
Results
Out of 86 patients, 49 (56.9%) had tumors with p53 overexpression and 60 (69.7%) with Mdm2 overexpression, respectively. Forty (46.4%) tumors were positive for both antibodies, including seven of the eight p53 mutated cases (Taubert et al., 1996) , and 17 (19.8%) tumors showed neither p53 nor Mdm2 positivity (Table 1) . A total of 24 (27.9%) patients had a relapse; 18 of them died (15 with positivity for both antibodies). Among the 37 (43.0%) patients who died because of the disease, 28 (75.7%) had tumors with Mdm2/p53 co-overexpression.
Univariate analysis of the relationships between staining and the attributes of adjustment in multivariate tests showed a signi®cant correlation (P=0.011) only for grading, but not for tumor entity and tumor localization (data not shown). In the multivariate Cox's analysis we found strong correlations between Mdm2 and p53 staining and overall survival as well as relapsefree survival (Table 1) . In an unstrati®ed interpretation, Mdm2 overexpression has a relative risk (rr) of 6.51 (P=0.0049) and p53 of 3.95 (P=0.0015) for overall survival.
In a strati®ed analysis describing Mdm2 results with regard to p53, we determined four groups with a dierent prognosis for overall survival and for relapsefree survival: (i) Mdm27/p537 (ii) Mdm27/p53+ (iii) Mdm2+/p537 and (iv) Mdm2+/p53+ ( Figure  1 ). The most striking group is the one with Mdm2/p53 co-overexpression, where a relative risk of 18.77 (P=0.006) for overall survival and of 7.8 (P=0.006) for relapse-free survival were found. multivariate prognostic relevance of isolated Mdm2 and of coincident Mdm2/p53 overexpression for overall and relapse-free survival in STS. Two previous univariate analyses which examined p53 and Mdm2 separately had shown controversial results for clinical relevance (Cordon-Cardo et al., 1994; Reid et al., 1996) . Further studies are required in order to establish whether the prognostic relevance of Mdm2/p53 cooverexpression is related to sarcoma development generally.
These ®ndings are unexpected, because overexpression of Mdm2 can substantially decrease wild-type and mutant p53 expression (Haupt et al., 1997; Kubbutat et al., 1997) . But modi®cation of either Mdm2 or p53, such as by phosphorylation, may protect from Mdm2-induced p53 degradation (Kubbutat et al., 1997) . In p53 the N-terminal region with a transcriptional activation domain is required for p53-dependent apoptosis (Chen et al., 1996) . Mdm2 can bind to the N-terminus of p53 protein (Kussie et al., 1996) and inhibits G1 arrest and apoptosis function of p53 (Chen et al., 1996) . Furthermore, apart from direct Mdm2/p53 interactions by highly speci®c binding (Kussie et al., 1996) , both proteins can function side by side without complexing (Otto and Deppert, 1993) . Thus Mdm2 can be oncogenic independently of p53, via activation of the E2F1/DP1 transcription factors (Martin et al., 1995) or via interaction with the RB protein (Xiao et al., 1995) . Mdm2 protein binds to C-terminal fragment of RB (amino acids 792-928) and may perturb RB suppression of E2F function (Xiao et al., 1995) . Furthermore, RB protein is cleaved by an ICE-like protease C-terminal (Asp886/Gly887) including Mdm2 binding site. The extent of this cleavage correlates with induction of apoptosis (JaÈ nicke et al., 1996) . It would be of interest to investigate if Mdm2 binding may disturb cleavage of RB and succeeding induction of apoptosis.
The present data suggest that, apart from the independent eects of Mdm2 and p53, there are much more than additive eects in the case of combined overexpression. The detection of Mdm2 and p53 cooverexpression has de®ned a clinical risk factor in STS with the highest prognostic relevance (rr=18.77) described until now. This ®nding constrains us to consider alternative therapeutic concepts which take the causal risk factors for these STS patients into consideration. A combined gene therapy with a p53 gene construct and mdm2 antisense has been suggested.
Materials and methods
We included 86 adult patients (44 men, 42 women) with primary STS of the extremities (22.1% arm, 77.9% leg) in stage T1 (24.4%) or T2 (75.6%) N0 M0 who had undergone primary radical surgical tumor resection (54.7% wide excision, 45.3% compartment resection) in our hospital (between 1986 and 1994) . The 86 STS are composed of the six most common entities: 26 (30.2%) liposarcomas, 20 (23.3%) malignant ®brous histiocytomas, 18 (20.9%) ®brosarcomas, nine (10.5%) malignant peripheral nerve sheath tumors, seven (8.1%) rhabdomyosarcomas and six (7.0%) leiomyosarcomas. A total of 15 (17.4%) patients had had grade 1, 39 (45.4%) grade 2 and 32 (37.2%) grade 3 tumors. In eight out of the 86 (9.3%) tumors we had previously identi®ed p53 mutations (Taubert et al., 1996) . The median follow-up for the living patients was 56.1 (31 ± 102) months and the mean age was 49 (19 ± 74) years. No patient had received pre-operative radiotherapy or chemotherapy. For all the patients and tumors, clinicopathologic data were assessed as described (WuÈ rl et al., 1997) .
We applied a monoclonal Mdm2 antibody 19E3 and p53 antibody DO-1, using a previously published immunohistochemical procedure (Taubert et al., 1996; WuÈ rl et al., 1997) . The staining rate of N-terminal binding DO-1 antibody showed the best correlation to prognosis (WuÈ rl et al., 1997) . Tumors were considered positive (indicating overexpression) when more than 10% of the neoplastic cells were stained. Statistical analysis started with a univariate evaluation of prognostic factors in a log-rank test and was followed by a multivariate cox regression analysis adjusted to grading, tumor size, localization, entity and the kind of surgical resection. 
